FLUARIX® Influenza Virus Vaccine, 2010-2011 Formula

Catalog No. NR-31799

This reagent is the property of the U.S. Government.

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

Manufacturer:

GlaxoSmithKline Biologicals, Dresden, Germany

Product Description:

NR-31799 is a split virus vaccine prepared from influenza viruses A/California/07/2009 NYMC X-181 (H1N1)pdm09, A/Victoria/210/2009 NYMC X-187 (H3N2) (an A/Perth/16/2009-like virus) and B/Brisbane/60/2008 that were predicted to circulate in the United States during the 2010 to 2011 influenza season.

NR-31799 was prepared from influenza viruses propagated in embryonated chicken eggs. Each of the influenza viruses was produced and purified separately. After harvesting the virus-containing fluids, each influenza virus was concentrated and purified by zonal centrifugation using a linear sucrose density gradient solution containing detergent to disrupt the viruses. Following dilution, the vaccine was further purified by diafiltration. Each influenza virus solution was inactivated by the consecutive effects of sodium deoxycholate and formaldehyde leading to the production of a "split virus." Each inactivated split virus was then suspended in sodium phosphate-buffered isotonic sodium chloride solution. The vaccine was formulated from the three split virus solutions.

The hemagglutinin content was standardized according to U.S. Public Health Service requirements. Each 0.5 mL of vaccine contains the recommended ratio of 15 µg of the hemagglutinin antigen for each of the three influenza strains recommended for the 2010-2011 Northern Hemisphere influenza season: A/California/07/2009 NYMC X-181 (H1N1)pdm09, A/Victoria/210/2009 NYMC X-187 (H3N2) (an A/Perth/16/2009-like virus) and B/Brisbane/60/2008.[1,2]

Please note that this vaccine preparation is being released for research use only and not for human use. Vaccines produced for the 2010-2011 season are now past their expiration dates.

Material Provided:

Each syringe contains 0.5 mL of split virus vaccine in sodium phosphate-buffered isotonic sodium chloride solution. The product is preservative-free and does not contain thimerosal.

Packaging/Storage:

NR-31799 is packaged in a 0.5 mL prefilled syringe. The product is provided on refrigerated bricks and should be stored at 2°C to 8°C immediately upon arrival. Do not freeze.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: FLUARIX® Influenza Virus Vaccine, 2010-2011 Formula, NR-31799."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmbl5/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

© 2011/2013 American Type Culture Collection (ATCC). All rights reserved.

References:

1. Fiore, A. E., et al. "Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010." MMWR Recomm. Rep. 59 (2010): 1-62. PubMed: 20689501.
2. http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm112850.htm

ATCC® is a trademark of the American Type Culture Collection.

Support Provided by NIAID

BEI Resources
www.beiresources.org

E-mail: contact@beiresources.org
Tel: 800-359-7370
Fax: 703-365-2898

© 2011/2013 American Type Culture Collection (ATCC). All rights reserved.